Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRDMT1 | O14717 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.33 |
| ▸ | AHCY | P23526 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1583282 | 0.93 | NNMT (0.33) | TRDMT1NNMTADORA1EHMT1CARM1 | |
| SCHEMBL6443389 | 0.89 | HPGD (0.37) | TYMP | |
| SCHEMBL6895651 | 0.86 | AHCY (0.35) | TRDMT1NNMTCARM1AHCYDOT1L | |
| SCHEMBL6898692 | 0.86 | AHCY (0.35) | TRDMT1NNMTCARM1AHCYDOT1L | |
| SCHEMBL8583121 | 0.83 | P2RX3 (0.39) | TRDMT1NNMTADORA1CARM1DOT1L | |
| SCHEMBL2109084 | 0.83 | TRDMT1 (0.36) | TRDMT1NNMTADORA1CARM1AHCY | |
| SCHEMBL15879332 | 0.82 | TRDMT1 (0.36) | TRDMT1NNMTADORA1CARM1AHCY | |
| SCHEMBL1582886 | 0.82 | EHMT1 (0.47) | TRDMT1NNMTADORA1EHMT1CARM1 | |
| SCHEMBL7914645 | 0.81 | TRDMT1 (0.37) | TRDMT1NNMTADORA1CARM1AHCY | |
| SCHEMBL4557136 | 0.80 | NNMT (0.34) | TRDMT1NNMTADORA1CARM1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313752-B1 | METHODS FOR SYNTHESIZING NUCLEOSIDE DERIVATIVES | RIBOZYME PHARM INC (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-6686463-B2 | FEWER SYNTHETIC STEPS; INVOLVES FORMATION OF A 5',4'-BRIDGING SILYL PROTECTING GROUP TO FORM A FUSED SILOXANE ON THE FURAN RING | SIRNA THERAPEUTICS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TRDMT1 68/4885NNMT 22/4885ADORA1 652/4885 |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TRDMT1 96/4885NNMT 22/4885ADORA1 826/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TRDMT1 69/4885NNMT 19/4885ADORA1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.